The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
Open accessAbstract
SUMMARY Background MYC gene rearrangement (MYC-R) is present in approximately 10% of aggressive B-cell lymphomas with approximately half harboring a BCL2 gene rearrangement (BCL2-R). Multiple retrospective studies of R-CHOP show an inferior outcome in patients with MYC-R, both alone and with BCL2-R and/or BCL6-R, and suggest better outcomes with more aggressive treatment. In the current study, we aimed to determine the outcome of DA-EPOCH-R, an aggressive infusional treatment regimen, in untreated MYC-R aggressive B-cell lymphomas. Methods Final analysis of a prospective multi-center study of DA-EPOCH-R (dose-adjusted treatment: etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituxiomab) in 53 patients with untreated MYC-R aggressive B-cell lymphomas. DAEPOCH-R was scheduled to be administered with central nervous system prophylaxis for 6 cycles. Primary endpoints included event-free and overall survival. The study was registered at ClinicalTrials.gov (NCT01092182). Findings Patient characteristics included median age 61 (range 29–80) years, stage III/IV disease in 43 (81%), and high-intermediate/high international prognostic score (IPI) in 26 (49%) patients. Characteristics were similar among patients with confirmed MYC-R single-hit (n=19) versus those with a BCL2-R and/or BCL6-R, termed double-hit, (n=24) lymphomas. With a median follow up of 55.6 (Interquartile range: 50.5–61.1) months, the 48-month EFS and OS for all patients was 71% and 77%, respectively, with no differences among patients with single versus double-hit tumors or age < versus ≥ 60 years. The EFS at 48-months for low/low-intermediate (0–2) versus high-intermediate/high (3–5) IPI was 89% versus 50%, respectively, for all patients, and 92% versus 55% for double-hit patients. Toxicity included grade 4 neutropenia and thrombocytopenia on 53% and 13% of cycles, respectively, and fever with neutropenia occurred on 19% of cycles. There were 3 treatment related deaths. Interpretation In this study, DA-EPOCH-R produced durable remissions in MYC-R aggressive B-cell lymphomas and should be considered for the treatment of these diseases. Funding Cancer Trials Support Unit and Center for Cancer Research, National Cancer Institute, USA, and Genentech Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Self-citation
Cited by
Bartlett, N. L., Wilson, W. H., Jung, S.-H., Hsi, E. D., Maurer, M. J., Pederson, L. D., Polley, M.-Y. C., Pitcher, B. N., Cheson, B. D., Kahl, B. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01994 · Cited by 434
Self-citationSusanibar‐Adaniya, S., & Barta, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26151 · Cited by 388
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
Ghilardi, G., Fraietta, J. A., Gerson, J. N., Van Deerlin, V. M., Morrissette, J. J. D., Caponetti, G. C., Paruzzo, L., Harris, J. C., Chong, E. A., Susanibar Adaniya, S. P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02826-w · Cited by 270
Metadata
- Authors
- Dunleavy, K., Fanale, M. A., Abramson, J. S., Noy, A., Caimi, P. F., Pittaluga, S., Parekh, S., Lacasce, A., Hayslip, J. W., Jagadeesh, D., Nagpal, S., Lechowicz, M. J., Gaur, R., Lucas, A., Melani, C., Roschewski, M., Steinberg, S. M., Jaffe, E. S., Kahl, B., Friedberg, J. W., Little, R. F., Bartlett, N. L., & Wilson, W. H.
- Venue
- The Lancet Haematology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 5
- Issue
- 12
- Pages
- e609-e617
- ISSN
- 2352-3026 (ISSN-L)
- OpenAlex
- W2902608107
- Cited by
- 230
- References
- 1
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. https://app.cochat.ai/papers/10.1016/s2352-3026(18)30177-7
- The paper
- Dunleavy, K., Fanale, M. A., Abramson, J. S., Noy, A., Caimi, P. F., Pittaluga, S., Parekh, S., Lacasce, A., Hayslip, J. W., Jagadeesh, D., Nagpal, S., Lechowicz, M. J., Gaur, R., Lucas, A., Melani, C., Roschewski, M., Steinberg, S. M., Jaffe, E. S., Kahl, B., . . . Wilson, W. H. (2018). Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(18)30177-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.